. 2016 May 20;7(27):42650–42660. doi: 10.18632/oncotarget.9516

Table 1. Baseline clinical features of 362 patients with ESCC.

Group	Total	%	HB/RDW				p value
Group	Total	%	<0.989	%	≥0.989	%	p value
Gender
Male	268	74.0	54	61.4	214	78.1	0.003^*
Female	94	26.0	34	38.6	60	21.9	0.003^*
Age(years)
≤60	217	59.9	51	58.0	166	60.6	0.708
>60	145	40.1	37	42.0	108	39.4	0.708
Tumor grade
I-II	270	74.6	69	78.4	201	73.4	0.339
III	92	25.4	19	21.6	73	26.6	0.339
Lymph nodes metastasis
Negative	194	53.6	40	45.5	154	56.2	0.086
Positive	168	46.4	48	54.5	120	43.8	0.086
Depth of tumor invasion
Tis-T2	95	26.2	15	17.0	80	29.2	0.026^*
T3-T4	267	73.8	73	83.0	194	70.8	0.026^*
TNM stage
I-II	203	56.1	39	44.3	164	59.9	0.013^*
III	159	43.9	49	55.7	110	40.1	0.013^*
Tumor location
Upper	38	10.5	4	4.5	34	12.4	0.052
Middle	229	63.3	55	62.5	174	63.5
Lower	95	26.2	29	33.0	66	24.1
GPS
0	280	77.3	65	73.9	215	78.5	0.382
1-2	82	22.7	23	26.1	59	21.5	0.382
Smoking
Never	129	35.6	38	43.2	91	33.2	0.097
Ever	233	64.4	50	56.8	183	66.8	0.097
Tumor size (cm)
≤3.5	186	51.4	37	42	149	54.4	0.050
>3.5	176	48.6	51	58	125	45.6	0.050
NLR
Median	2.2		2.1		2.2		0.004^*
Mean±SD	2.9±4.0		3.9±6.9		2.5±2.3		0.004^*
PLR
Median	117		126		113		0.001^*
Mean±SD	130±67		150±79		124±62		0.001^*
Hemoglobin(g/dL)
Median	13.7		11.7		14.1		<0.001^*
Mean±SD	13.5±1.6		11.6±1.5		14.1±1.1		<0.001^*
RDW (%)
Median	12.4		13.7		12.2		<0.001^*
Mean±SD	12.6±1.1		13.7±1.5		12.2±0.7		<0.001^*
Treatment
Surgery alone	289	79.8	63	71.6	226	82.5	0.022^*
Surgery+ adjuvant RT/CT	73	20.2	25	28.4	48	17.5	0.022^*

Abbreviations: ESCC=esophageal squamous cell carcinoma; HB=hemoglobin; RDW=red cell distribution width; GPS=Glasgow prognostic score; NLR=neutrophil to lymphocyte ratio; PLR= platelet to lymphocyte ratio; SD=standard deviation; RT=radiotherapy; CT=chemotherapy

p < 0.05